The global genomic cancer testing market is estimated to be valued at US$ 16.15 billion in 2023 and is projected to exhibit a CAGR of 16.1% from 2023 to 2030, according to a new report published by Coherent Market Insights.
Market Overview:
Genomic cancer testing involves analyzing the DNA or RNA of cancer cells to identify specific genetic variations that contribute to the development and progression of cancer. This helps healthcare professionals in the selection of targeted therapies and personalized treatment plans for patients. The advantages of genomic cancer testing include improved diagnostic accuracy, better treatment outcomes, and reduced healthcare costs.
Market Key Trends:
One key trend in the genomic cancer testing market is the growing adoption of precision medicine. Precision medicine aims to tailor medical treatment to the individual characteristics of each patient, including their genetic makeup. Genomic cancer testing plays a crucial role in identifying the specific genetic mutations in cancer cells, enabling targeted therapies that are designed to inhibit the growth and spread of cancer. The increasing focus on precision medicine is expected to drive the demand for genomic cancer testing tools and services.
Porter’s Analysis
Threat of New Entrants: The genomic cancer testing market has a moderate threat of new entrants. The barriers to entry, such as high research and development costs, regulatory requirements, and the need for advanced technology, pose challenges for new players. However, the increasing demand for genomic testing and potential market growth may attract new entrants.
Bargaining Power of Buyers: The bargaining power of buyers in the genomic cancer testing market is moderate. Although buyers have access to a wide range of options and can switch between testing providers, the importance of accurate and reliable test results limits their bargaining power. Additionally, the presence of large diagnostic companies with established market presence gives them some leverage.
Bargaining Power of Suppliers: The bargaining power of suppliers in the genomic cancer testing market is high. Key suppliers, such as Illumina and Thermo Fisher Scientific, hold significant market share and have established relationships with testing providers. This positions them to negotiate favorable terms and prices. Additionally, suppliers of advanced technology and reagents have a strong bargaining position due to the specialized nature of the market.
Threat of New Substitutes: The threat of new substitutes in the genomic cancer testing market is low. Genomic testing has become an integral part of cancer diagnosis and treatment, offering unique insights into the personalized treatment approach. There are currently no viable substitutes that offer the same level of precision and detail as genomic testing.
Competitive Rivalry: The genomic cancer testing market is highly competitive, with several key players operating in the market. These include Illumina, Thermo Fisher Scientific, Qiagen, Roche, and Invitae, among others. These companies compete on factors such as technology advancements, product portfolio, pricing, and market reach. The competition is intense, driving continuous innovation and market growth.
Key Takeaways
The Global Genomic Cancer Testing Market Demand is expected to witness high growth, exhibiting a CAGR of 16.1% over the forecast period (2023-2030). This growth is primarily attributed to the increasing prevalence of cancer, rising demand for personalized medicine, and advancements in genomic technologies. Genomic testing allows for precise diagnosis, personalized treatment plans, and better patient outcomes.
In terms of regional analysis, North America is anticipated to be the fastest-growing and dominating region in the genomic cancer testing market. Factors such as favorable reimbursement policies, the presence of key companies, and a high prevalence of cancer contribute to the growth of this region. Additionally, ongoing research and development activities and increasing investments in healthcare infrastructure further drive market growth in North America.
Key players operating in the genomic cancer testing market include Illumina, Thermo Fisher Scientific, Qiagen, Roche, Foundation Medicine, Invitae, NeoGenomics Laboratories, and Myriad Genetics, among others. These companies are continuously involved in strategic collaborations, acquisitions, and product innovations to strengthen their market presence and gain a competitive edge. The market is highly consolidated, with the major players accounting for a significant market share.
Read More - https://www.pressreleasebulletin.com/genomic-cancer-testing-market-share-size-analysis-trend-and-forecast/
